Judah Frommer Stock Analyst Profile - Morgan Stanley Research Coverage - Stocknear

Judah Frommer

Stock Analyst at Morgan Stanley

(5)
# 151
Out of 5,459 analysts
195
Total ratings
Success rate
Average return
44 Stocks
Name Action PT Current % Upside Ratings Updated
TRVI Trevi Therapeutics
Initiates Coverage On: Overweight
18
8 125% 1 Aug 21, 2025
APLS Apellis Pharmaceutic...
Maintains: Equal-Weight
25 26
28.22 -7.87% 2 Jul 2, 2025
BPMC Blueprint Medicines
Maintains: Equal-Weight
102 129
129.46 -0.36% 2 Jun 5, 2025
CLDX Celldex Therapeutics
Maintains: Overweight
46 43
22.6 90.27% 2 May 9, 2025
ABVX Abivax
Assumes: Equal-Weight
12
79.43 -84.89% 1 Mar 20, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
22 24
8.82 172.11% 2 Mar 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
31 22
32.91 -33.15% 3 Feb 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
8 6
6.46 -7.12% 2 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
81 106
69.9 51.65% 2 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
35
12.02 191.18% 1 Oct 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
13
2.06 531.07% 1 Apr 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Equal-Weight
3
2.49 20.48% 1 Mar 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
40
2.9 1279.31% 8 Aug 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
4
n/a n/a 3 Aug 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
13
1.39 835.25% 5 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
30
47.82 -37.26% 8 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
23
19.3 19.17% 5 Aug 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
50
49.78 0.44% 9 Jul 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
141
18.07 680.3% 13 Jun 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
156
17.16 809.09% 5 May 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
9
4.57 96.94% 5 May 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
175 138
n/a n/a 6 May 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
21 22
24.47 -10.09% 2 Apr 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
8 7
5.91 18.44% 3 Mar 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 1
n/a n/a 4 Mar 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
11 8
6.63 20.66% 5 Mar 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
46
27.4 67.88% 5 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
7 7
2.18 221.1% 6 Mar 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
51 55
15.75 249.21% 3 Feb 28, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
46
134.53 -65.81% 1 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underperform
4 4
n/a n/a 1 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
14 10
n/a n/a 2 Oct 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
47 49
101.37 -51.66% 4 Nov 5, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
328 370
949.52 -61.03% 2 Oct 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
24 31
77.63 -60.07% 6 Sep 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
65 76
80.32 -5.38% 8 Sep 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
182
111.27 63.57% 6 Aug 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
107
112.86 -5.19% 13 Aug 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
90 95
130.6 -27.26% 10 Jul 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
18
19.52 -7.79% 1 Jul 21, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
93 116
144.41 -19.67% 12 Jun 10, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
31 38
97.27 -60.93% 4 May 22, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
18 22
144.51 -84.78% 1 May 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
33 35
67.97 -48.51% 9 Apr 29, 2020